-
Something wrong with this record ?
Chemotherapy versus chemoradiotherapy in borderline resectable and locally advanced pancreatic adenocarcinoma
S. Argalácsová, M. Vočka, L. Petruželka, M. Ryska, P. Záruba, Z. Krška, V. Frýba, J. Ulrych, V. Černý, T. Tůma, D. Hoskovec
Language English Country Slovakia
Document type Journal Article
- MeSH
- Adenocarcinoma * pathology MeSH
- Chemoradiotherapy MeSH
- Humans MeSH
- Pancreatic Neoplasms * pathology MeSH
- Neoadjuvant Therapy MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Retrospective Studies MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
The role of radiotherapy in borderline resectable (BRPC) and locally advanced pancreatic carcinoma (LAPC) remains controversial. In our study, we retrospectively evaluated 48 patients with BRPC (14; 29.2%) and LAPC (34; 70. 8%) who underwent 6-8 cycles of induction mFOLFIRINOX chemotherapy alone (23; 47.9%) or 4-6 cycles of mFOLFIRINOX followed by hypofractionated radiotherapy (up to the total dose of 39.9 Gy in 15 fractions) (25; 52.1%). Survival parameters were evaluated using the Gehan-Breslow-Wilcoxon Test and compared by using the long-rank test. The addition of radiotherapy was not associated with better survival (16.9 months for chemotherapy only versus 15.9 months for the combined therapy; p=0.486), as well as for both subgroups (13.5 months vs. 18.3 months; p=0.679) and (20.7 months vs. 13.8 months; p=0.425) for BRPC and LAPC, respectively. A higher resection rate was seen in the BRPC group compared to the LAPC group (43% vs. 17.6%, respectively). Our study revealed a significantly higher rate of lung metastases in patients after the combination therapy compared to those treated by chemotherapy only (19% vs. 0%, respectively; p=0.045). Such a borderline result, however, prevents us from drawing clear conclusions about whether this is an artifact caused by the low number of patients or whether radiotherapy leads to a selection of stem cells with a predilection to the generalization to the lungs.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23017068
- 003
- CZ-PrNML
- 005
- 20231026105427.0
- 007
- ta
- 008
- 231013s2023 xo f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.4149/neo_2023_230409N193 $2 doi
- 035 __
- $a (PubMed)37498072
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xo
- 100 1_
- $a Argalácsová, Soňa $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 245 10
- $a Chemotherapy versus chemoradiotherapy in borderline resectable and locally advanced pancreatic adenocarcinoma / $c S. Argalácsová, M. Vočka, L. Petruželka, M. Ryska, P. Záruba, Z. Krška, V. Frýba, J. Ulrych, V. Černý, T. Tůma, D. Hoskovec
- 520 9_
- $a The role of radiotherapy in borderline resectable (BRPC) and locally advanced pancreatic carcinoma (LAPC) remains controversial. In our study, we retrospectively evaluated 48 patients with BRPC (14; 29.2%) and LAPC (34; 70. 8%) who underwent 6-8 cycles of induction mFOLFIRINOX chemotherapy alone (23; 47.9%) or 4-6 cycles of mFOLFIRINOX followed by hypofractionated radiotherapy (up to the total dose of 39.9 Gy in 15 fractions) (25; 52.1%). Survival parameters were evaluated using the Gehan-Breslow-Wilcoxon Test and compared by using the long-rank test. The addition of radiotherapy was not associated with better survival (16.9 months for chemotherapy only versus 15.9 months for the combined therapy; p=0.486), as well as for both subgroups (13.5 months vs. 18.3 months; p=0.679) and (20.7 months vs. 13.8 months; p=0.425) for BRPC and LAPC, respectively. A higher resection rate was seen in the BRPC group compared to the LAPC group (43% vs. 17.6%, respectively). Our study revealed a significantly higher rate of lung metastases in patients after the combination therapy compared to those treated by chemotherapy only (19% vs. 0%, respectively; p=0.045). Such a borderline result, however, prevents us from drawing clear conclusions about whether this is an artifact caused by the low number of patients or whether radiotherapy leads to a selection of stem cells with a predilection to the generalization to the lungs.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory slinivky břišní $x patologie $7 D010190
- 650 12
- $a adenokarcinom $x patologie $7 D000230
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a neoadjuvantní terapie $7 D020360
- 650 _2
- $a chemoradioterapie $7 D059248
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vočka, Michal $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Petruželka, Luboš $u Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Ryska, Miroslav $u Department of Surgery, Second Faculty of Medicine, Charles University and Military University Hospital in Prague, Prague, Czech Republic, Prague, Czech Republic
- 700 1_
- $a Záruba, Pavel $u Department of Surgery, Second Faculty of Medicine, Charles University and Military University Hospital in Prague, Prague, Czech Republic, Prague, Czech Republic
- 700 1_
- $a Krška, Zdeněk $u Department of Surgery, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Frýba, Vladimír $u Department of Surgery, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Ulrych, Jan $u Department of Surgery, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Černý, Vladimír $u Department of Radiology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Tůma, Tomáš $u Department of Radiology, Military University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Hoskovec, David $u Department of Surgery, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
- 773 0_
- $w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 70, č. 3 (2023), s. 468-475
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37498072 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026105422 $b ABA008
- 999 __
- $a ok $b bmc $g 2000543 $s 1203430
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 70 $c 3 $d 468-475 $e - $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
- LZP __
- $a Pubmed-20231013
